Fatty Acid Biosynthesis Disorders – Drugs In Development, 2024
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Fatty Acid Biosynthesis Disorders – Drugs In Development, 2024 report and make more profitable business decisions.
Fatty acid biosynthesis disorders (FABDs) are a group of inherited metabolic disorders that affect the ability of the body to use fatty acids as a source of energy. Fatty acids are long chains of carbon and hydrogen atoms that are stored in fat cells and can be broken down to produce energy when glucose (sugar) is not available. However, people with FABDs have defects in the enzymes or transport proteins that are involved in the process of fatty acid breakdown, also called fatty acid oxidation. This leads to a buildup of fatty acids or their byproducts in the blood and tissues, and a shortage of energy for the cells. FABDs can cause various symptoms depending on the type and severity of the disorder, such as low blood sugar, muscle weakness, heart problems, liver enlargement, brain damage, and developmental delays. FABDs are diagnosed by newborn screening tests, genetic tests, or biochemical tests that measure the levels of fatty acids or their metabolites in the blood or urine. Treatment of FABDs depends on the specific disorder, but usually involves dietary modifications, supplements, medications, and avoiding fasting or prolonged exercise. FABDs are rare disorders that affect about 1 in 10,000 to 50,000 people worldwide.
The Fatty Acid Biosynthesis Disorders drugs in development market research report provide comprehensive information on the therapeutics under development for Fatty Acid Biosynthesis Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fatty Acid Biosynthesis Disorders and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- Therapeutics in Development: Covering 35 molecules, with 28 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Fatty Acid Biosynthesis Disorders therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Fatty Acid Biosynthesis Disorders pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Fatty Acid Biosynthesis Disorders treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AceLink Therapeutics IncApteeus SAS
Autobahn Therapeutics Inc
Azafaros BV
Celularity Inc
Centers of Biomedical Research Network
Consortium Center for Biomedical Research Network
Duke University
Imstem Biotechnology Inc
IntraBio Ltd
Ironwood Pharmaceuticals Inc
JCR Pharmaceuticals Co Ltd
McMaster University
MedDay SA
Minoryx Therapeutics sl
Orpheris Inc
Orphi Therapeutics Inc
Polaryx Therapeutics Inc
Poxel SA
ReceptoPharm Inc
Reneo Pharmaceuticals Inc
Sanofi
Scenic Biotech BV
Shenzhen Geno-Immune Medical Institute
Shenzhen Second People's Hospital
SwanBio Therapeutics Inc
Taysha Gene Therapies Inc
Ultragenyx Pharmaceutical Inc
University of Massachusetts
Vigil Neuroscience Inc
Viking Therapeutics Inc